1. Home
  2. WLYB vs NVAX Comparison

WLYB vs NVAX Comparison

Compare WLYB & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo John Wiley & Sons Inc.

WLYB

John Wiley & Sons Inc.

HOLD

Current Price

$38.56

Market Cap

1.9B

ML Signal

HOLD

Logo Novavax Inc.

NVAX

Novavax Inc.

HOLD

Current Price

$8.58

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WLYB
NVAX
Founded
1807
1987
Country
United States
United States
Employees
5200
N/A
Industry
Books
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.6B
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
WLYB
NVAX
Price
$38.56
$8.58
Analyst Decision
Hold
Analyst Count
0
9
Target Price
N/A
$11.33
AVG Volume (30 Days)
646.0
4.4M
Earning Date
03-05-2026
05-07-2026
Dividend Yield
3.68%
N/A
EPS Growth
N/A
309.76
EPS
N/A
2.58
Revenue
N/A
$1,123,479,000.00
Revenue This Year
$1.04
N/A
Revenue Next Year
$2.36
N/A
P/E Ratio
$15.27
$3.47
Revenue Growth
N/A
64.69
52 Week Low
$29.16
$5.01
52 Week High
$45.16
$11.85

Technical Indicators

Market Signals
Indicator
WLYB
NVAX
Relative Strength Index (RSI) 69.84 38.44
Support Level $37.75 $8.01
Resistance Level $38.63 $9.05
Average True Range (ATR) 0.41 0.54
MACD 0.38 -0.23
Stochastic Oscillator 100.00 1.78

Price Performance

Historical Comparison
WLYB
NVAX

About WLYB John Wiley & Sons Inc.

John Wiley & Sons Inc is a publisher and a trusted leader in research and learning. The company segment includes: Research, which includes the reporting lines of Research Publishing and Research Solutions, and Learning includes the Academic and Professional reporting lines and consists of publishing, courseware, and assessments. Its industry-principal content, services, platforms, and knowledge networks are tailored to meet the evolving needs of its customers and partners, including researchers, students, instructors, professionals, institutions, and corporations. The company empowers knowledge-seekers to transform today's obstacles into tomorrow's brightest opportunities. For more than two centuries, the company has been delivering on its timeless mission to unlock human potential.

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.

Share on Social Networks: